Sangharsha Thapa
Publication Activity (10 Years)
Years Active: 2023-2024
Publications (10 Years): 9
Publications (10 Years): 9
Publications
- Sangharsha Thapa, Sangam Shah, Abhinav Bhattarai, Mohammad Yazdan Panah, Swati Chand, Omid Mirmosayyeb
- Sangharsha Thapa, Sangam Shah, Abhinav Bhattarai, Mohammad Yazdan Panah, Swati Chand, Omid Mirmosayyeb
- Mahtab Mohammadzamani, Kimia Kazemzadeh, Swati Chand, Sangharsha Thapa, Narges Ebrahimi, Mohammad Yazdan Panah, Vahid Shaygannejad, Omid Mirmosayyeb
- Mahtab Mohammadzamani, Kimia Kazemzadeh, Swati Chand, Sangharsha Thapa, Narges Ebrahimi, Mohammad Yazdan Panah, Vahid Shaygannejad, Omid Mirmosayyeb
- Niraj Neupane, Sangharsha Thapa, Amir Mahmoud, Abhinav Bhattarai, Anil Kc, Shreeja Shikhrakar, Sayuri Gurusinghe, Peter KuiodesDoes Caplacizumab for the management of thrombotic thrombocytopenic purpura increase the risk of relapse, exacerbation, and bleeding? An updated systematic review and meta-analysis based on revised criteria by the International Working Group for thrombotic thrombocytopenic purpura. EJHaem 5 (1) (2023)
- Niraj Neupane, Soon Khai Low, Himal Kharel, Sanket Bhattarai, Sangharsha Thapa, Amir A Mahmoud, Nishan Babu Pokhrel, Mohammad Ammad Ud Din, Peter A Kouides
- Niraj Neupane, Sangharsha Thapa, Abhinav Bhattarai, Kriti Ahuja, Ilana Schlam, Abhenil Mittal, Sara M Tolaney, Paolo Tarantino
- Mohammad Yazdan Panah, Yousef Mokary, Sangam Shah, Sangharsha Thapa, Swati Chand, Vahid Shayegannejad, Omid Mirmosayyeb
- Niraj Neupane, Sangharsha Thapa, Amir Mahmoud, Abhinav Bhattarai, Anil Kc, Shreeja Shikhrakar, Sayuri Gurusinghe, Peter KuiodesDoes Caplacizumab for the management of thrombotic thrombocytopenic purpura increase the risk of relapse, exacerbation, and bleeding? An updated systematic review and meta-analysis based on revised criteria by the International Working Group for thrombotic thrombocytopenic purpura. EJHaem 5 (1) (2023)